Why is Glenmark Pharmaceuticals Ltd. falling/rising?

Short-Term Price Movement and Market Context

Despite the recent fall, Glenmark’s stock has demonstrated resilience over longer periods. The one-week return shows a decline of 4.05%, which is steeper than the Sensex’s 2.73% drop, indicating some short-term underperformance relative to the broader market. However, over the past month, the stock has gained 4.89%, contrasting with the Sensex’s 8.84% loss, and year-to-date it has risen by 5.01% while the benchmark index has declined by 10.74%. These figures suggest that while the stock faced pressure on 17-Mar, it remains a strong performer in a challenging market environment.

On the day in question, Glenmark underperformed its sector by 2.01%, and the share price was trading below its five-day moving average, though it remained above longer-term averages such as the 20-day, 50-day, 100-day, and 200-day moving averages. This technical positioning may indicate a short-term correction or profit booking after recent gains.

Investor participation also declined, with delivery volumes on 16-Mar falling by nearly 39% compared to the five-day average. This reduced trading activity could have contributed to the price softness, reflecting cautious sentiment among market participants despite the stock’s liquidity remaining adequate for sizeable trades.

Strong Financial Performance Underpinning Long-Term Growth

Glenmark Pharmaceuticals’ fundamentals remain robust, which supports its strong performance over the medium and long term. The company reported net sales of ₹9,947.49 crores for the latest six-month period, marking a substantial growth rate of 45.83%. Profit after tax (PAT) for the same period stood at ₹2,026.77 crores, reflecting significant earnings growth.

The company’s return on capital employed (ROCE) for the half-year is an impressive 35.65%, indicating efficient use of capital to generate profits. Additionally, Glenmark’s return on equity (ROE) is 23.5%, which, combined with a price-to-book value of 6.3, suggests an attractive valuation relative to its peers. The stock trades at a discount compared to the average historical valuations of similar companies, making it appealing for value-conscious investors.

Over the past year, Glenmark has delivered a remarkable 49.26% return to shareholders, vastly outperforming the Sensex’s 2.56% gain. This performance is underpinned by an extraordinary 890.4% increase in profits, highlighting the company’s strong earnings momentum. The PEG ratio stands at zero, signalling that the stock’s price growth is well supported by its earnings expansion.

Institutional investors hold a significant 39.33% stake in Glenmark, reflecting confidence from sophisticated market participants who typically conduct thorough fundamental analysis. This institutional backing often provides stability and can be a positive indicator for future performance.

Consistent Outperformance and Market Recognition

Glenmark’s consistent returns over the last three years have been exceptional, with a cumulative gain of 385.08%, far exceeding the Sensex’s 31.18% over the same period. The stock has outperformed the BSE500 index in each of the last three annual periods, underscoring its strong market position and operational excellence.

The company is also highly rated by MarketsMojo, ranking within the top 1% of over 4,000 stocks analysed. It holds the 10th position among mid-cap companies and 21st across the entire market, reflecting its solid fundamentals and growth prospects.

While the recent price dip on 17-Mar may reflect short-term profit-taking or technical adjustments, Glenmark Pharmaceuticals’ underlying financial strength, attractive valuation metrics, and institutional support suggest that the stock remains well positioned for continued growth over the medium to long term.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →